Visalytics
Visalytics
approved EB-2 (NIW)

Assistant Professor

Drug Delivery · Syria · 2022-03-23

Processing Time
65 days
Decision Date
2022-03-23
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to continue research in the development of new drug delivery carriers based on nanotechnology using a one-step reproducible process. This work focuses on developing DNA and RNA vaccines and treating diseases such as cancer, Alzheimer's, and diabetes. Additionally, the endeavor includes the development of new pediatric drugs designed to mask unpleasant tastes to ease ingestion for children.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor has national importance as it bolsters the U.S. pharmaceutical industry and addresses critical health issues like cancer and diabetes.

2 Well-positioned to Advance the Endeavor Met

The petitioner is well-positioned due to a Ph.D., a history of 47 publications, 270 citations, and funding from major Malaysian ministries.

3 Balance of Interests Met

On balance, it is beneficial to waive the job offer requirement because the petitioner's work supports safer drug delivery and provides significant economic output.

Why This Petition Was Approved

The petition was approved based on the petitioner's Ph.D. in pharmaceutical science and a strong record of 47 peer-reviewed journal articles, 1 book, and 1 book chapter. The evidence included 270 citations, 21 completed peer reviews, and 4 expert recommendation letters. The case demonstrated alignment with FDA priorities and significant economic impact on the $1.3 trillion U.S. pharmaceutical industry.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Reference Letters Independent
Grants
Original Contributions
Government Alignment

Similar Cases

Scientist

Pharmaceuticals · India

WeGreened EB-2 (NIW) approved
North Carolina 132 days 2024-05-17
The petitioner proposes to continue her research in pharmaceutical sciences, specifically focusing on advancing drug repurposing and the development of nanoparticle-based delivery systems. Her work aims to create smarter, more efficient ways to deliver medications for critical diseases such as cancer and COVID-19. This research is intended to provide faster, cost-effective pathways for translating laboratory discoveries into viable clinical treatments.
View Case

Postdoctoral Researcher

Nanotechnology · Jordan

WeGreened EB-2 (NIW) approved
Maryland 90 days 2023-05-13
The petitioner proposes to improve the delivery of mRNA therapeutics to increase the effectiveness of gene therapies for incurable conditions. His work focuses on formulating and characterizing novel nanoparticles and developing advanced animal models to test therapeutics for brain diseases like Alzheimer's and anti-cancer drug delivery.
View Case

Others

Materials Science · China

WeGreened EB-2 (NIW) approved
California 341 days 2025-05-29
The petitioner proposes to continue her research into advanced nanomedicines, specifically focusing on nanoparticle-based drug delivery systems. Her work involves developing porous silicon nanoparticles designed for the improved delivery of siRNA and proteins to intracellular targets to treat cancer, brain injuries, and toxin exposure. The goal is to create both prophylactic and responsive therapeutic platforms for acute and chronic illnesses.
View Case

Associate Professor

Pharmaceuticals · Saudi Arabia

WeGreened EB-2 (NIW) approved
505 days 2025-05-16
The petitioner proposes to continue research in pharmaceutics, specifically focusing on drug nano-delivery systems and the development of smart, sustainable alternative drug dosage forms. This work utilizes pharmaceutical technology to improve the deliverability, targetability, efficacy, and safety of drugs. The intended impact is to address critical needs in drug formulation and patient care within the United States.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from Syria

Case data sourced from publicly available petition decisions and case studies. Decision date: 2022-03-23.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 65 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,814
Success Rate 53.6%
Sustained 2,046
Dismissed 1,672

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Syria All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist